Highlights • Interrater agreement for both the 2019 and 2005 Bosniak classifications was comparable, showing fair to moderate agreement among resident raters. • The Bosniak 2019 version has increased the…
Highlights • Racial and insurance disparities impact access to integrated care. • Advanced cancer stages increase likelihood of integrated care. • Treatment and hospital factors minimally affect delivery of integrated…
Highlights • Identified 12 gut microbial taxa potentially linked to prostate cancer risk using MR analysis. • Employed robust statistical methods to ensure reliability of causal inference results. • Explored…
Highlights • In preclinical studies, it has been demonstrated that antihistamines may reverse macrophage immunosuppression, reactivate t-cell cytotoxicity, and enhance the immunotherapy response. • By use of individual patient data…
Highlights • Real-world study of US adults with la/mUC receiving first-line therapy. • Most received platinum-based chemotherapy (48.2%) or PD-1/L1 inhibitor (35.5%). • All first-line therapies had short survival, high…
Highlights • Initial trial results examining the efficacy of adjuvant immune checkpoint inhibitors in the setting of high-risk, resected muscle invasive urothelial carcinoma provided disparate results. • In this systematic…
Highlights • High grade and very high grade NMIBC has the potential to reoccur and progress and the BCG intravesical therapy is an adjuvant gold standard treatment. • Smoking impacts…
Highlights • The carcinogenic pathways of heavy metals/ trace elements in bladder cancer are studied. • They include alterations in MD, OS/ROS, and p38-MAPK pathway. • This data provides a…
Highlight • Neoadjuvant therapy significantly improved DFS and OS in RCC patients with IVC thrombus. • Patients receiving neoadjuvant therapy had a 2-year recurrence-free survival of 70.9%. • Pathological complete…
Highlights • Partial cystectomy serves as a less invasive alternative for muscle-invasive bladder cancer. • The 5-year Overall Survival rate was 55%, Cancer Specific Survival was 67%, and Recurrence-Free Survival…
